or
www.spandidos-publications.com
Home  | About  | Contact
Spandidos Logo
Advanced Search
Login  | Register


congress_banner

main_table_top_image
   Current Issue Early Online Archive Manuscript Submission About Editor and Editorial Board Sitemap
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content

Authors:
Daniela Terracciano, Claudia Mazzarella, Angelina Di Carlo, Angela Mariano, Matteo Ferro, Giuseppe Di Lorenzo, Antonio Giordano, Vincenzo Altieri, Sabino De Placido, Vincenzo Macchia

Affiliations:
Department of Cellular and Molecular Biology and Pathology ‘L. Califano’, University of Naples ‘Federico II’, I-80131 Naple, Italy

Doi:
10.3892/or_00000848

Pages:
213-217

Abstract:

Prostate cancer is one of the most frequently diagnosed cancer in men. Treatment by radical prostatectomy, radiotherapy and anti-androgen drugs is successful in patients with localized cancer. However, prolonged androgen deprivation often leads to hormone refractory condition, associated with disease relapse. ErbB1 and ErbB2 activity has been correlated with androgen-independence. We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. We found that PC-3 cell growth was inhibited by GW2974, whereas NSE and chromogranin A cell contents were stimulated and osteopontin cytosol level was not affected. The present data may have clinical implications for the treatment of advanced prostate cancer.

OPEN ACCESS ARTICLE

Oncology Reports

July 2010
Volume 24 Number 1


Viewing options: Sign up for eToc alerts

Share this article:



main_table_bottom_image